Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Seanergy Maritime Holdings Corp (SHIP) Q2 Earnings and Revenues Surpass Estimates
Seanergy Maritime Holdings Corp (SHIP) Q2 Earnings and Revenues Surpass Estimates

Seanergy Maritime Holdings Corp (SHIP) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.77 per share a

Gear Up for Yelp (YELP) Q2 Earnings: Wall Street Estimates for Key Metrics
Gear Up for Yelp (YELP) Q2 Earnings: Wall Street Estimates for Key Metrics

In its upcoming report, Yelp (YELP) is predicted by Wall Street analysts to post quarterly earnings of $0.48 per share, reflecting a decline of 11.1% compared to the same period last year

Countdown to Royalty Pharma (RPRX) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Countdown to Royalty Pharma (RPRX) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS

Analysts on Wall Street project that Royalty Pharma (RPRX) will announce quarterly earnings of $1.10 per share in its forthcoming report, representing an increase of 14.6% year over year. Revenues

Exploring Analyst Estimates for Wynn (WYNN) Q2 Earnings, Beyond Revenue and EPS
Exploring Analyst Estimates for Wynn (WYNN) Q2 Earnings, Beyond Revenue and EPS

The upcoming report from Wynn Resorts (WYNN) is expected to reveal quarterly earnings of $1.20 per share, indicating an increase of 7.1% compared to the year-ago period. Analysts forecast revenues

Exploring Analyst Estimates for Zimmer (ZBH) Q2 Earnings, Beyond Revenue and EPS
Exploring Analyst Estimates for Zimmer (ZBH) Q2 Earnings, Beyond Revenue and EPS

In its upcoming report, Zimmer Biomet (ZBH) is predicted by Wall Street analysts to post quarterly earnings of $1.98 per share, reflecting a decline of 1.5% compared to the same period last year

Uniti Group (UNIT) Q2 FFO and Revenues Lag Estimates
Uniti Group (UNIT) Q2 FFO and Revenues Lag Estimates

Uniti Group (UNIT) came out with quarterly funds from operations (FFO) of $0.36 per share, missing the Zacks Consensus Estimate of $0.7 per share. This compares to FFO of $0.34 per share a year ago

Portillo's Inc. (PTLO) Meets Q2 Earnings Estimates
Portillo's Inc. (PTLO) Meets Q2 Earnings Estimates

Portillo's Inc. (PTLO) came out with quarterly earnings of $0.12 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.1 per share a year ago. These figures are

Unlocking Q2 Potential of Plains All American (PAA): Exploring Wall Street Estimates for Key Metrics
Unlocking Q2 Potential of Plains All American (PAA): Exploring Wall Street Estimates for Key Metrics

Wall Street analysts expect Plains All American Pipeline (PAA) to post quarterly earnings of $0.30 per share in its upcoming report, which indicates a year-over-year decline of 3.2%. Revenues are

Somnigroup International (SGI) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Somnigroup International (SGI) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates

Wall Street analysts expect Somnigroup International (SGI) to post quarterly earnings of $0.51 per share in its upcoming report, which indicates a year-over-year decline of 19.1%. Revenues are

IPG Photonics (IPGP) Q2 Earnings and Revenues Surpass Estimates
IPG Photonics (IPGP) Q2 Earnings and Revenues Surpass Estimates

IPG Photonics (IPGP) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.45 per share a year ago. These

Mesa Labs (MLAB) Lags Q1 Earnings and Revenue Estimates
Mesa Labs (MLAB) Lags Q1 Earnings and Revenue Estimates

Mesa Labs (MLAB) came out with quarterly earnings of $2.32 per share, missing the Zacks Consensus Estimate of $2.46 per share. This compares to earnings of $2.83 per share a year ago. These figures

Global Ship Lease (GSL) Beats Q2 Earnings and Revenue Estimates
Global Ship Lease (GSL) Beats Q2 Earnings and Revenue Estimates

Global Ship Lease (GSL) came out with quarterly earnings of $2.67 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.46 per share a year ago. These

Great Lakes Dredge & Dock (GLDD) Beats Q2 Earnings and Revenue Estimates
Great Lakes Dredge & Dock (GLDD) Beats Q2 Earnings and Revenue Estimates

Great Lakes Dredge & Dock (GLDD) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.11 per share a year

Curious about Insulet (PODD) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Curious about Insulet (PODD) Q2 Performance? Explore Wall Street Estimates for Key Metrics

In its upcoming report, Insulet (PODD) is predicted by Wall Street analysts to post quarterly earnings of $0.93 per share, reflecting an increase of 69.1% compared to the same period last year

What Analyst Projections for Key Metrics Reveal About Texas Roadhouse (TXRH) Q2 Earnings
What Analyst Projections for Key Metrics Reveal About Texas Roadhouse (TXRH) Q2 Earnings

Analysts on Wall Street project that Texas Roadhouse (TXRH) will announce quarterly earnings of $1.95 per share in its forthcoming report, representing an increase of 8.9% year over year. Revenues

Insights Into BCE (BCE) Q2: Wall Street Projections for Key Metrics
Insights Into BCE (BCE) Q2: Wall Street Projections for Key Metrics

Wall Street analysts forecast that BCE (BCE) will report quarterly earnings of $0.52 per share in its upcoming release, pointing to a year-over-year decline of 8.8%. It is anticipated that

Fox (FOXA) Beats Q4 Earnings and Revenue Estimates
Fox (FOXA) Beats Q4 Earnings and Revenue Estimates

Fox (FOXA) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $0.9 per share a year ago. These figures are

Illumina (ILMN) Reliance on International Sales: What Investors Need to Know
Illumina (ILMN) Reliance on International Sales: What Investors Need to Know

Have you evaluated the performance of Illumina's (ILMN) international operations for the quarter ending June 2025? Given the extensive global presence of this genetic testing tools company

Can These 6 Energy Stocks Surpass Q2 Earnings Estimates?
Can These 6 Energy Stocks Surpass Q2 Earnings Estimates?

The oil/energy sector is under pressure in the second quarter of 2025, as falling crude oil prices and narrowing profit margins create a difficult operating environment. With roughly 25% of S&P 500

DuPont's Earnings & Sales Top Estimates in Q2 on Higher Volumes
DuPont's Earnings & Sales Top Estimates in Q2 on Higher Volumes

DuPont de Nemours, Inc. DD registered second-quarter 2025 profit from continuing operations of $238 million or 54 cents per share. In the year-ago quarter, the company recorded a profit of $176

Curis (CRIS) Reports Q2 Loss, Beats Revenue Estimates
Curis (CRIS) Reports Q2 Loss, Beats Revenue Estimates

Curis (CRIS) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $1.99. This compares to a loss of $2.03 per share a year ago. These figures are

3 Top Dividend Stocks to Maximize Your Retirement Income
3 Top Dividend Stocks to Maximize Your Retirement Income

Here's an eye-opening statistic: older Americans are more afraid of running out of money than of death itself.

And unfortunately, even retirees who have built a nest egg have good reason to be

Core Molding Technologies (CMT) Q2 Earnings and Revenues Beat Estimates
Core Molding Technologies (CMT) Q2 Earnings and Revenues Beat Estimates

Core Molding Technologies (CMT) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.73 per share a year ago

Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?
Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?

Exelixis’ (EXEL) lead drug, Cabometyx, a tyrosine kinase inhibitor (TKI), maintains a dominant position for the treatment of renal cell carcinoma (RCC) in both the frontline immuno-oncology (IO)

ADTRAN Misses Q2 Earnings Estimates Despite Higher Revenues
ADTRAN Misses Q2 Earnings Estimates Despite Higher Revenues

ADTRAN Holdings, Inc. ADTN reported mixed second-quarter 2025 results, with the top line surpassing the Zacks Consensus Estimate but the bottom line missing the same.The company recorded a top-line